CQDM and CPDC are pleased to announce the launch of the 2026 Call for Ideas: New Canadian Approaches in Radiopharmaceuticals, a national initiative designed to identify and support innovative Canadian technologies, discoveries, and companies that can contribute to the next generation of radiopharmaceuticals.
Canada has developed internationally recognized expertise across the radiopharmaceutical value chain, from target discovery and isotope production to clinical development and commercialization. Through this initiative, CQDM and CPDC seek to discover emerging Canadian innovations and connect promising teams with CPDC’s scientific experts and investment team.
CPDC has played a key role in the creation and growth of globally recognized Canadian radiopharmaceutical companies, including Fusion Pharmaceuticals and AtomVie Global Radiopharma. This Pitch Day will provide selected participants with a unique opportunity to receive feedback from CPDC, and to explore potential direct Seed and Series A investment, in-licensing, and collaboration opportunities in the radiopharmaceutical space.
In addition, CQDM will offer guidance to selected participants interested in pursuing non-dilutive funding opportunities through relevant CQDM programs, including SynergiQc and/or others.
Selected applicants will be invited to present their technology, company, or research program to CPDC’s scientific experts and investment team during a virtual CQDM-CPDC Pitch Day. Please note that this call for ideas is not a grant competition.
Research Focus Areas
We are particularly interested in innovative technologies that address important clinical needs and demonstrate a clear pathway toward translation and commercialization, including:
- Radiotherapeutics
- Radiotheranostic pairs
- Novel radiopharmaceutical targets and targeting approaches
- Radiodiagnostics
- New applications and indications beyond oncology
- Technologies enabling radiopharmaceutical discovery, development, manufacturing, or scale-up
We are seeking ideas that combine scientific excellence, innovation, and strong commercial potential to help strengthen Canada’s position as a global leader in radiopharmaceutical innovation.
Who Can Apply
Applications are welcome from:
- Canadian startups and SMEs
- Established Canadian biotechnology and pharmaceutical companies
- Researchers at Canadian universities and research institutions
- Academic-industry partnerships and multidisciplinary teams
Projects may be at various stages of development, provided they demonstrate innovation and potential commercial relevance in the radiopharmaceutical sector.
Deadline
Submission deadline is October 15, 2026. All submissions will be reviewed jointly by CQDM and CPDC.
Please submit the completed non-confidential application pitch deck (download here) by email to Mathieu Paquette at mpaquette@cqdm.org.
Selection Process
All submissions will be reviewed jointly by CQDM and CPDC. Selected applicants will be invited to participate in the virtual CQDM-CPDC Pitch Day on December 2, 2026, where they will present their technology directly to CPDC’s investment team.
For more information, visit the CQDM website or contact Mathieu Paquette at mpaquette@cqdm.org.
About CQDM
Facilitator of biopharma innovation
CQDM is a non-profit biopharmaceutical research consortium whose mission is to support and facilitate multi-stakeholder collaborative R&D aimed at accelerating the translation, of innovative technologies by the biopharma industry into solutions that address unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. For more information, consult our website www.cqdm.org and follow us on LinkedIn.
About CPDC
CPDC (Centre for Probe Development and Commercialization) is a not-for-profit advancing nuclear medicine in Canada and beyond through strategic investments, expert guidance and innovative radiopharmaceutical development to benefit patients globally. In the past 18 years, CPDC has created four Canadian commercial entities that have accelerated the availability of radiopharmaceuticals to the Canadian and global medical community. CPDC will continue to identify and advance critical radiopharmaceuticals to meet the needs of patients and physicians through our collaborations with partners including industry, academia, and government. For more information on CPDC visit www.cpdc.ca and follow on LinkedIn.